In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes.

ABSTRACT: Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. Given gepotidacin's in vitro activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the treatment of infections caused by clinically relevant anaerobic organisms.

SUBMITTER: Hackel MA 

PROVIDER: S-EPMC8846401 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature